Teva Pharma Industries Ltd ADR

The Trump administration has selected 10 companies, including AbbVie, Amgen, Pfizer, and GSK, for a new pilot program that tests a rebate model for drugs purchased under a federal program benefiting uninsured and low-income patients. The 340B Rebate Model Pilot takes effect on January 1 and allows the selected manufacturers to verify and pay rebates for 21 discounted drugs purchased under the government's 340B drug pricing program, rather than offering savings upfront as under the current discount model. The participating drugmakers are AbbVie, Amgen, Astellas, AstraZeneca, Bristol Myers, GSK, Merck, Pfizer, and Teva. The Health Resources and Services Administration, the HHS unit overseeing the program, said the approach helps address compliance concerns proactively rather than relying primarily on retrospective reviews, audits, and dispute resolution processes. The pilot marks the Trump administration's second attempt to overhaul the decades-old drug discount program, after a federal judge blocked HRSA's first 340B rebate pilot following a case brought by hospital groups last year.

Teva Pharmaceutical and Samsung Bioepis said Thursday they have entered a global license, development, and commercialization agreement for up to six potential biosimilar candidates, of which two are confirmed investigational candidates: SB41, referencing Fasenra, and SB44, referencing Ilaris. Under the terms, Samsung Bioepis will handle development, regulatory registration, and manufacturing of the biosimilars, while Teva will commercialize them in global markets including the United States, Europe, and Canada, with an option to expand the partnership to other territories. The deal reinforces the long-standing partnership between the two companies, which has already produced the U.S. commercialization of EPYSQLI. The companies also expanded that earlier agreement to include OPUVIZ in Canada, reflecting a shared approach to combining complementary capabilities to broaden access to biosimilar medicines across global markets.

Teva Pharmaceutical Industries CEO Richard Francis said the company has shifted from being viewed primarily as a generics manufacturer toward a biopharmaceutical company with a growing innovative medicines portfolio, while maintaining and expanding its generics operations. Speaking with J.P. Morgan analyst Chris Schott, Francis said Teva's innovative business grew 40% in the second quarter, with innovative sales rising from about $1.2 billion at the end of 2022 to approximately $1 billion per quarter now, and the company expects mid-single-digit growth after 2026. He said gross margin has risen from 48% when he became CEO to about 55%, and Teva is targeting a 30% operating margin by 2027, supported by a cost-efficiency program expected to generate $700 million in savings after investment by the end of 2027. Francis highlighted a pipeline including duvakitug, anti-IL-15 programs, long-acting olanzapine, ecopipam for Tourette syndrome and UZEDY, and said Teva expects a product launch each year for the next five years, followed by launches roughly every 18 months. He reiterated confidence in more than $3 billion in peak annual sales for AUSTEDO, called AJOVY a potential billion-dollar brand, and estimated a $1.5 billion to $2 billion franchise opportunity for UZEDY and long-acting olanzapine, while noting Teva now has 15 biosimilars on the market and another 14 in its pipeline.

Teva Pharmaceuticals announced new data showing that healthcare providers prioritize drowsiness risk, the duration of available long-term response data and drug-drug interaction profile when selecting a VMAT2 inhibitor for tardive dyskinesia in patients aged 55 and older. In a discrete choice experiment, 489 healthcare providers ranked somnolence risk, accounting for 26.8% to 36.2% of decision-making weight, and short-term symptom improvement, at 24.4% to 29.5%, as their top priorities, followed by dose formulation at 16.7% to 20.2% and drug-drug interaction risk at 14.4% to 17.3%. Applying those preferences across four patient profiles, AUSTEDO, also known as deutetrabenazine, had the highest predicted choice probability, driven mainly by somnolence risk, duration of long-term response data and drug-drug interaction. The findings were presented at Psych Congress, held September 15 to 19, 2026, in New Orleans. A separate interim analysis from the IMPACT-TD Registry found that among patients with probable tardive dyskinesia who remained untreated with any VMAT2 inhibitor for 24 months, roughly 89% to 96% experienced at least a mild global impact and 60% to 74% experienced moderate-to-severe impact, while 55% to 69% reported stable or worsening severity with no evidence of spontaneous resolution.

Teva Pharmaceuticals announced new post hoc data from the pivotal Phase 3 SOLARIS trial showing that its investigational once-monthly subcutaneous long-acting injectable olanzapine, TEV-'749, achieved high rates of stabilization and long-term efficacy in adults with schizophrenia. In the open-label long-term treatment period, 231 of 411 participants, or 56 percent, achieved stabilization, and among those 231 stabilized participants only 10, or 4 percent, relapsed. Among 183 participants treated with TEV-'749 for six or more months, 39, or 21 percent, met criteria for remission. Separate analyses simulating inpatient switching found that initiating TEV-'749 one day after the last dose of oral or short-acting intramuscular olanzapine produced predictable olanzapine exposures within established oral therapeutic ranges, and a metabolic outcomes analysis found TEV-'749's profile consistent with daily oral olanzapine with no clear dose-dependent pattern. The findings were presented at Psych Congress in New Orleans, and a PDUFA decision from the FDA is expected for TEV-'749 in the fourth quarter of 2026, while the European Medicines Agency accepted the Marketing Authorization Application in May 2026. TEV-'749 is not approved by any regulatory authority for any use at this time.

Teva Pharmaceutical Industries said its "Pivot to Growth" strategy has entered its second phase, with management pointing to branded-medicine momentum, a stabilized generics business, an expanding biosimilars portfolio and a strengthened balance sheet. Speaking at a Morgan Stanley event, President and Chief Executive Officer Richard Francis said the strategy, launched in 2023, rests on four pillars: delivering on the growth engine, stepping up innovation, creating a generics powerhouse, and focusing the business and capital allocation. Francis said Teva has cut debt and secured investment-grade ratings from all three major agencies more than a year ahead of its projection, completed an oversubscribed refinancing in the prior week, and converted ADS shares into ordinary shares to broaden investor access. He reiterated confidence that AUSTEDO can eventually exceed $3 billion in sales, ahead of the prior $2.5 billion target, and said AJOVY is approaching the $1 billion threshold faster than expected, while UZEDY and long-acting olanzapine together represent a $1.5 billion to $2 billion opportunity. Teva has 11 biosimilars on the market and expects to add roughly nine more by the end of the decade, and Francis said the company is on track to exceed its $800 million biosimilars target for 2027 a year early. Chief Medical Officer Eric Hughes said the TL1A therapy duvakitug, developed with Sanofi for ulcerative colitis and Crohn's disease, showed the highest phase 2 results reported for the class, and that ecopipam, a first-in-class D1 antagonist for Tourette's disease, received priority review with a potential launch in the first half of 2027.

Teva Pharmaceutical Industries priced an offering of roughly $4.9 billion equivalent in senior notes, split across five tranches. The tranches comprise €1 billion of 4.25% senior notes due 2033, €500 million of 4.625% notes due 2036, $1 billion of 5.5% notes due 2034, $1 billion of 5.75% notes due 2037 and $1.2 billion of 5.25% notes due 2032. Teva expects to use the proceeds, along with cash on hand, to fund debt redemptions, related expenses and other corporate purposes. The company plans to redeem several existing notes, including its 6.75% notes due 2028, its 7.875% and 7.375% sustainability-linked notes due 2029, and portions of notes due 2027 and 2030, and it also expects to redeem all of its 8.125% sustainability-linked notes due 2031. Settlement of the new notes is expected on or around September 16.

BioXcel Therapeutics filed for Chapter 11 bankruptcy on August 27, just 11 weeks before the FDA is due to rule on an expanded label for its only approved product, Igalmi. The New Haven, Connecticut-based biotech, which had raised debt against a launch that never materialized, saw its cash run out before the catalyst date. The company's credit agreement with Oaktree Capital Management and the Qatar Investment Authority was amended 14 times, and by July lenders required a definitive strategic transaction. Teva Pharmaceuticals has agreed to act as stalking horse bidder, offering $57.5 million in cash at closing plus up to $67.5 million tied to the timing of FDA approval for the at-home use of Igalmi. Nasdaq will delist the stock on September 8, and common shareholders are unlikely to recover anything given the secured debt of about $112 million.

DelveInsight projects the ulcerative colitis market across the seven major markets—the US, EU4, UK, and Japan—will grow from approximately USD 9.4 billion in 2025 at a CAGR of 7.6% through 2036, driven by novel targeted therapies and a robust pipeline of late-stage candidates. Among these, Abivax's obefazimod, a first-in-class oral miR-124 enhancer, met its primary endpoint in Phase III ABTECT induction studies, with a pooled placebo-adjusted clinical remission rate of 16.4% at Week 8. Merck's tulisokibart, acquired via Prometheus Biosciences, achieved clinical remission in the Phase 3 ATLAS-UC study, while Roche's afimkibart, from its $7.1 billion Telavant acquisition, showed a 35% remission rate in Phase IIb TUSCANY-2. Johnson & Johnson and Protagonist Therapeutics' icotrokinra, a first-in-class oral IL-23 receptor antagonist, met its primary endpoint in the Phase 2b ANTHEM-UC trial, and Teva and Sanofi's duvakitug, backed by a $400 million Blackstone funding deal, is in Phase III. These therapies target unmet needs in moderate-to-severe disease, with the market shifting toward IL-23 inhibitors and oral advanced therapies, though biosimilars and established anti-TNFs remain widely used.

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Limited, has agreed to serve as the stalking-horse bidder for substantially all assets of BioXcel Therapeutics, Inc. and certain affiliates through a court-supervised Chapter 11 auction. The proposed consideration includes $57.5 million in cash at closing and up to $67.5 million in contingent cash, for a maximum of $125 million, plus specified assumed liabilities. The portfolio includes IGALMI, the associated BXCL501 program, and other assets beyond neuroscience. A competing bidder may still submit a superior offer, and any transaction requires bankruptcy-court approval. The pending supplemental new drug application seeks to expand IGALMI's label to include at-home treatment of acute agitation associated with schizophrenia or bipolar I or II disorder in adults, with an FDA target action date of November 14, 2026.

Teva Pharmaceuticals and the Trump Administration have announced a shared commitment to lower the cost of select medicines for U.S. Medicaid patients, with a final agreement expected to support continued investment in innovation and manufacturing. The deal, if finalized, would align U.S. Medicaid pricing for certain drugs with leading developed markets through the GENEROUS framework, and include a Most-Favored-Nation commitment for future innovative launches. Teva has also offered a reserve of active pharmaceutical ingredients for public health needs and pledged further investment in U.S. manufacturing. Negotiations remain confidential, and the agreement is part of the administration's broader drug pricing priorities.

Teva Pharmaceuticals International has made a bid to acquire a range of neuroscience assets from BioXcel Therapeutics for a total deal value of $125m, as part of BioXcel's voluntary Chapter 11 proceedings in the US Bankruptcy Court for the District of Delaware. The proposed transaction would give Teva worldwide rights to Igalmi (dexmedetomidine) sublingual film and the investigational BXCL501, which is under FDA review for potential at-home use in treating acute agitation linked to schizophrenia or bipolar disorder. Teva has been designated as the stalking horse bidder, setting the initial offer in the Section 363 auction process, and would receive a break-up fee if it loses. The upfront consideration is $57.5m, with up to $67.5m in contingent payments tied to FDA approval timing and sales milestones. BioXcel has also secured $19m in debtor-in-possession financing to maintain operations during the sale.

Alvotech announced that the U.S. Food and Drug Administration has accepted for review its Biologics License Application for AVT80, a proposed interchangeable biosimilar to Entyvio (vedolizumab) for subcutaneous administration via prefilled syringe and autoinjector. This acceptance follows the May acceptance of Alvotech's BLA for AVT16, the intravenous presentation, meaning the company's vedolizumab biosimilar program now covers both intravenous and subcutaneous forms. Under a partnership with Teva Pharmaceutical Industries, Alvotech handles development and manufacturing while Teva manages commercialization. The BLA is supported by analytical, pharmacokinetic, and immunogenicity data, and a pivotal pharmacokinetic study met all primary endpoints in February 2026. If approved, AVT80 would expand biosimilar options for patients with ulcerative colitis and Crohn's disease in the United States.

Teva Pharmaceutical stock surged roughly 12.3% this week after the company announced it will replace its American depositary receipts with common stock listed directly on the New York Stock Exchange starting September 14. The move is expected to attract more institutional and retail investors. Teva also reported second-quarter results, with sales of $4.1 billion beating analyst estimates by about $70 million, though adjusted earnings of $0.02 per share missed the $0.11 consensus. Full-year guidance calls for adjusted earnings between $1.91 and $2.11 per share and revenue between $16.5 billion and $16.85 billion.

Teva Pharmaceutical Industries will replace its American Depositary Shares with a direct listing of ordinary shares on the New York Stock Exchange, with trading set to begin September 14. ADS holders will receive a one-for-one exchange as the company aims to broaden its shareholder base and optimize its cost of capital. The move could also open the door for inclusion in major indices, potentially boosting visibility and institutional interest. Teva, which has a market capitalization of $40.71 billion, has seen its stock gain 108% over the past 52 weeks, driven by strong sales of branded drugs like Austedo, Ajovy, and Uzedy. Analysts hold a consensus Strong Buy rating with a price target of $38.73, representing a 9.6% upside from current levels.

The inflammatory bowel disease market across the seven major markets was valued at USD 21 billion in 2025, with the United States accounting for the largest share. The total number of incident cases of inflammatory bowel disease in the seven major markets was around 181 million in 2025. Growth is being fueled by the rising prevalence of Crohn's disease and ulcerative colitis, increased adoption of advanced biologic therapies, and the emergence of novel mechanisms of action targeting IL-23, TL1A, and S1P pathways. Key pipeline candidates include Abivax's ABX464, Merck's Tulisokibart, RedHill Biopharma's RHB-204, and Teva Pharmaceuticals and Sanofi's duvakitug, among others. The anticipated launch of these next-generation therapies is expected to reshape the treatment landscape and address unmet needs in biologic-refractory patients.

Teva Pharmaceutical Industries raised its full-year 2026 revenue guidance, driven by a 43% year-over-year increase in combined revenue from its innovative medicines AUSTEDO, AJOVY, and UZEDY. The company lifted the midpoint of its overall 2026 revenue outlook by $75 million, while second-quarter revenue of approximately $4.1 billion declined 1% from a year earlier as lower sales from generic Revlimid were largely offset by growth in the innovative portfolio. AUSTEDO generated $676 million in U.S. revenue, up 33%, and its full-year guidance was raised to a range of $2.45 billion to $2.6 billion. UZEDY posted quarterly revenue of $77 million, up 43%, with its full-year forecast increased by $15 million at the midpoint to $270 million to $290 million, and AJOVY's global revenue rose 56% to $244 million, prompting a $90 million midpoint increase in its full-year outlook to $850 million to $870 million. Teva reported a GAAP net loss of $576 million, or $0.49 per share, including a $724 million in-process research and development expense from the Emalex Biosciences acquisition, while non-GAAP earnings per share were $0.02, or $0.63 excluding that impact. Free cash flow rose 31% to $622 million, and the company ended the quarter with net debt of $12.9 billion and a net-debt-to-EBITDA ratio of 2.8 times, or 2.3 times excluding the Emalex acquisition.

Ford Motor, Teva Pharmaceutical, and Manhattan Associates were among the biggest stock gainers Wednesday, while Parsons led the losers after slashing its guidance. Ford shares rose 8% after the automaker beat Q2 revenue and adjusted EPS estimates and raised its full-year outlook, despite a net loss from one-time charges. Manhattan Associates jumped 25% on better-than-expected Q2 results and strong guidance, and Teva Pharmaceutical gained 10% after raising its 2026 innovative drug portfolio outlook. On the downside, Parsons tumbled 38% after cutting its FY2026 revenue and profit guidance, O-I Glass fell 19% on a Q2 earnings miss and lowered outlook, and Avis Budget Group slid 12% following a revenue and earnings miss.

Teva Pharmaceutical Industries' shift from generic to branded drugs has driven an 85% share price surge over the past 12 months, and its pipeline candidate duvakitug could fuel another 50% rally. Branded drugs like Austedo, Ajovy, and Uzedy are growing sales at mid-double-digit rates, while generics now account for just over half of total revenue. Management expects 2026 earnings per share between $1.91 and $2.11, down from $2.65 in 2025 due to the dilutive impact of the Emalex Biosciences acquisition, but forecasts a 30% increase in operating profit and adjusted EBITDA starting next year. Duvakitug, co-developed with Sanofi for ulcerative colitis and Crohn's disease, is entering phase 3 trials after promising phase 2b results, with peak annual sales projected at $2 billion to $5 billion. With the stock trading at less than 10 times estimated 2027 earnings, further progress on duvakitug could trigger another major rally.

A federal appeals court on Monday revived a lawsuit brought by Teva Pharmaceutical Industries against Eli Lilly over an agreement that allowed Teva to market a generic version of Lilly's osteoporosis drug Forteo. The two drugmakers brokered a settlement agreement in 2018 that allowed Teva to launch its generic teriparatide as early as 2019, but the US FDA eventually granted Forteo an additional three years of exclusivity in 2020. Teva began marketing its generic version in December 2023 and then sued Lilly in 2024, alleging that the extra exclusivity period delayed its generic marketing. The appellate court stated that the 2018 agreement does not clearly indicate whether or when the settlement agreement or relevant covenants expired, and those questions cannot be resolved in Lilly's favor based solely on the text of the agreement and the complaint.

The global chronic obstructive pulmonary disease market is projected to grow from USD 25.06 billion in 2025 to USD 40.39 billion by 2035, at a compound annual growth rate of 4.89 percent, according to a new report by SNS Insider. Bronchodilators held the largest revenue share in 2025 at 48.10 percent, while corticosteroids are expected to register the fastest CAGR of 5.04 percent through 2035. Chronic bronchitis accounted for 60.80 percent of market revenue in 2025, and the treatment segment captured 65.10 percent of revenue. North America led with over 38.40 percent market share in 2025, while Asia Pacific is forecast to grow at the highest CAGR of 5.99 percent. Key players include AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Teva Pharmaceutical Industries.

The Motley Fool compares Novartis and Teva Pharmaceutical Industries as investment options for 2026, favoring Teva for long-term investors due to its lower valuation multiples. Novartis reported fiscal 2025 revenue of nearly $56.7 billion with net income of almost $14 billion, while Teva achieved revenue of nearly $17.3 billion and net income of $1.4 billion. Teva's first-quarter 2026 results exceeded expectations with revenue of almost $4 billion and net income of $369 million, driven by strong sales of Ajovy, Uzedy, and Austedo which grew more than 40% in local currencies. Novartis saw first-quarter volume rise 14% to $13.5 billion with net income of almost $3.2 billion, and its pipeline includes remibrutinib, a potential blockbuster for autoimmune disorders. Teva's forward price-to-earnings ratio of 17.0 and price-to-sales ratio of 2.9 are lower than Novartis's 17.6 and 5.3, respectively, making Teva more attractive on a valuation basis despite projected sales decline in 2026.

Teva Pharmaceuticals and Polpharma Biologics have entered a global licensing agreement granting Teva exclusive rights to commercialize Polpharma Biologics' proposed biosimilar to Ocrevus, upon regulatory approval. Polpharma Biologics will retain full responsibility for development and manufacturing of the biosimilar candidate, while Teva will handle regulatory submissions and, once approved, commercialization of both intravenous and subcutaneous formulations in the United States, Europe, Brazil, Canada, Australia, New Zealand, Israel, and Turkey. The deal is expected to combine Polpharma Biologics' biosimilar development expertise with Teva's commercial footprint and supports Teva's Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.

Jefferies analyst Dennis Ding maintained a Buy rating and a $40 price target on Teva Pharmaceutical Industries, citing the recent share weakness as a buying opportunity. The decline was attributed to broader market factors and investor reactions to management comments on the vitiligo program, along with a clinical trial update shifting the expected primary completion date. After discussions with Teva's investor relations team, confidence in the vitiligo program remained unchanged, with data still expected shortly after the July 4 weekend. Separately, Teva announced real-world findings showing that its drugs AUSTEDO and AUSTEDO XR were associated with improvements in chorea symptoms and quality of life for Huntington's disease patients, with 74% of patients reporting improved movements after starting therapy.

Teva Pharmaceutical Industries announced new clinical and real-world findings supporting Austedo and Austedo XR in tardive dyskinesia, alongside the European launch of its aflibercept biosimilar AHZANTIVE. Results from the IMPACT-TD study showed that patients with mild symptoms experienced improvements in involuntary movements and daily functioning after treatment, while updated data from the ongoing three-year RIM-TD study found more than half of participants achieved a treatment response by week 15, with additional patients benefiting from continued therapy. The company also expanded its international footprint through the rollout of AHZANTIVE across several countries including France, Germany, Spain, and the Netherlands, with further market entries planned later in the year. The biosimilar is approved for multiple retinal disorders and strengthens Teva's ophthalmology portfolio as part of its strategy to increase access to biologic medicines.

Teva Pharmaceutical Industries submitted a New Drug Application to the U.S. FDA for ecopipam, a first-in-class selective dopamine D1 receptor antagonist for pediatric Tourette syndrome. The filing is supported by positive Phase 3 data published in JAMA Neurology and backed by Orphan Drug and Fast Track designations. If approved, ecopipam could become the first new FDA-approved treatment for pediatric Tourette syndrome in more than a decade, reinforcing Teva's push into higher-margin innovative neurology. However, the orphan-sized pediatric population and typical FDA review timeline mean the drug is unlikely to change Teva's near-term earnings picture on its own. Investors remain focused on execution of recent launches, generic price pressure, and cash generation amid a share price that has pulled back after a multi-year run.

Teva Pharmaceutical Industries is accelerating its shift from generics to branded drugs, with first-quarter 2026 sales of its three key innovative medicines—Austedo, Ajovy, and Uzedy—rising 41% year over year to $838 million. Global Austedo sales climbed 41% to $578 million, driven by strong prescription growth and the launch of a once-daily formulation, while Ajovy revenue increased 35% in constant currency to $196 million and Uzedy sales jumped 62% to $63 million. The company expects Austedo to exceed $2.5 billion in annual revenue by 2027 and $3 billion by 2030, and it projects total branded product revenues of more than $5 billion by 2030. Teva also closed its acquisition of Emalex and its Tourette syndrome therapy ecopipam in June, and it has filed for FDA approval of the drug. Branded medicines now account for more than 20% of Teva's revenue, up from about 9% in 2022.

Clarivate Plc released its 2025 Sustainability Report, highlighting a 24% decline in total greenhouse gas emissions. Total emissions across Scope 1, 2 and 3 fell from 96,666 tCO₂e in 2024 to 73,110 tCO₂e in 2025. Sustainability-certified workplaces now cover approximately 38% of the company's total square footage. ProQuest One Sustainability was adopted by more than 400 institutions and named a Library Journal Best Reference Database for 2025. Colleagues contributed over 36,000 volunteer hours to community initiatives, and Clarivate partnered with Teva to support antimicrobial stewardship programs in Germany and Kenya.

Teva Pharmaceutical Industries released new clinical data showing its Austedo and Austedo XR therapies improved symptoms in a majority of tardive dyskinesia and Huntington's disease chorea patients, reinforcing the drug's market position as the company's biggest growth driver. The three-year study presented at Psych Congress Elevate found over 50% of tardive dyskinesia patients saw symptom improvement within 15 weeks, with an additional 23% achieving success with long-term treatment, while 60% to 71% of Huntington's chorea patients experienced improvement. Teva's innovative brands—Austedo, Ajovy, and Uzedy—grew revenue 41% year over year in the first quarter of 2026, helping lift non-GAAP gross margin to 52.9% and EPS 72% to $0.31, even as total revenue edged up just 2% to $4 billion. However, full-year 2026 revenue guidance of $16.4 billion to $16.8 billion, implying flat to slightly negative growth, disappointed Wall Street and has weighed on the stock since the April 29 earnings release. The company also faces supply-chain risks from Middle East conflicts and generic competition eroding other portfolio segments, though its pipeline of six biosimilars awaiting regulatory decisions this year and the recent FDA approval of biosimilar Ponlimsi offer additional catalysts.

Medincell SA reported full year 2026 earnings, highlighting progress in its Shift to Growth strategy and a rise in royalties from UZD, while total income dipped to $24.3 million from $27.7 million a year earlier due to the absence of milestone payments. Net sales of UZD by Teva reached $215 million, up from $141 million, and Olanzapine LAI is on track for a U.S. launch in the fourth quarter of 2026 with FDA submissions accepted. Operating expenses increased to EUR 45 million from EUR 38.5 million, resulting in an operating loss of EUR 20.8 million, though the company maintains a strong cash position of EUR 85 million. CEO Christophe Duarte noted Teva's conservative guidance and expects Olanzapine LAI to launch immediately upon approval, while CFO Stefan Postic addressed foreign exchange exposure by aligning expenses with USD revenues where possible. The company is expanding its pipeline with 15 active programs and confirmed that AbbVie's first candidate will start clinical development in 2027.